Drug Profile
Eculizumab biosimilar - Biocad
Alternative Names: BCD-148Latest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Biocad
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 22 Apr 2022 No development reported - Phase-III for Paroxysmal nocturnal haemoglobinuria in Russia (IV) (NCT04060264)
- 30 Dec 2020 Biocad completes a phase-III clinical trial in Paroxysmal nocturnal haemoglobinuria in Russia (IV) (NCT04060264)
- 07 Apr 2019 Biocad completes a phase I trial in Paroxysmal nocturnal haemoglobinuria (In volunteers) in Russia (IV) (NCT04027803)